INTRAVITREAL BEVACIZUMAB FOR THE TREATMENT OF CHOROIDAL HEMANGIOMAS.

IF 2.3 2区医学 Q2 OPHTHALMOLOGY

Retina-The Journal of Retinal and Vitreous Diseases Pub Date : 2025-03-01 Epub Date: 2025-02-17 DOI:10.1097/IAE.0000000000004323

Hassan E Elkayal, Mandeep S Sagoo, Guy S Negretti

{"title":"INTRAVITREAL BEVACIZUMAB FOR THE TREATMENT OF CHOROIDAL HEMANGIOMAS.","authors":"Hassan E Elkayal, Mandeep S Sagoo, Guy S Negretti","doi":"10.1097/IAE.0000000000004323","DOIUrl":null,"url":null,"abstract":"Purpose: To investigate the use of intravitreal bevacizumab for the treatment of subretinal fluid (SRF) and intraretinal fluid associated with circumscribed choroidal hemangiomas.Methods: This was a retrospective review of all patients treated with at least three bevacizumab injections for circumscribed choroidal hemangiomas-associated SRF between May 2020 and August 2023 in Moorfields eye hospital. Outcome measures included change in best-corrected visual acuity, change in patient-reported symptoms, change in SRF, and change in central subfield thickness. Data on further management after cessation of injections were analyzed.Results: The study included nine patients. Median best-corrected visual acuity was 6/19 before and 6/24 after injections ( P = 0.41). Central subfield thickness decreased from a median of 466 to 447 µ m ( P = 0.11). Two thirds of (n = 6) patients did not show any reduction in foveal SRF, one third (n = 3) showed a partial reduction, and no patients had a complete resolution of SRF. Eight patients received rescue-photodynamic therapy, and one received external beam radiotherapy. Best-corrected visual acuity changed from a median of 6/60 to a median of 6/12 after rescue treatment ( P = 0.63). The median central subfield thickness decreased significantly from 470 µ m to 249 µ m ( P = 0.01).Conclusion: Intravitreal bevacizumab is unlikely to be an effective treatment for exudative circumscribed choroidal hemangiomas.","PeriodicalId":54486,"journal":{"name":"Retina-The Journal of Retinal and Vitreous Diseases","volume":" ","pages":"501-508"},"PeriodicalIF":2.3000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11832178/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Retina-The Journal of Retinal and Vitreous Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/IAE.0000000000004323","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To investigate the use of intravitreal bevacizumab for the treatment of subretinal fluid (SRF) and intraretinal fluid associated with circumscribed choroidal hemangiomas.

Methods: This was a retrospective review of all patients treated with at least three bevacizumab injections for circumscribed choroidal hemangiomas-associated SRF between May 2020 and August 2023 in Moorfields eye hospital. Outcome measures included change in best-corrected visual acuity, change in patient-reported symptoms, change in SRF, and change in central subfield thickness. Data on further management after cessation of injections were analyzed.

Results: The study included nine patients. Median best-corrected visual acuity was 6/19 before and 6/24 after injections ( P = 0.41). Central subfield thickness decreased from a median of 466 to 447 µ m ( P = 0.11). Two thirds of (n = 6) patients did not show any reduction in foveal SRF, one third (n = 3) showed a partial reduction, and no patients had a complete resolution of SRF. Eight patients received rescue-photodynamic therapy, and one received external beam radiotherapy. Best-corrected visual acuity changed from a median of 6/60 to a median of 6/12 after rescue treatment ( P = 0.63). The median central subfield thickness decreased significantly from 470 µ m to 249 µ m ( P = 0.01).

Conclusion: Intravitreal bevacizumab is unlikely to be an effective treatment for exudative circumscribed choroidal hemangiomas.

查看原文本刊更多论文

玻璃体内贝伐单抗治疗脉络膜血管瘤。

目的：探讨使用玻璃体内贝伐单抗治疗与环形脉络膜血管瘤（CCH）相关的视网膜下（SRF）和视网膜内积液的方法：这是一项回顾性研究，研究对象是2020年5月至2023年8月期间在Moorfields眼科医院接受至少3次贝伐单抗注射治疗的所有CCH相关SRF患者。结果指标包括最佳矫正视力（BCVA）的变化、患者报告症状的变化、SRF的变化和中央子场厚度（CSFT）的变化。对停止注射后的进一步治疗数据进行了分析：研究包括 9 名患者。注射前 BCVA 中位数为 6/19，注射后为 6/24（p = 0.41）。CSFT 从中位数 466 μm 下降到 447 μm（p = 0.11）。三分之二（6 人）的患者眼窝 SRF 没有减少，三分之一（3 人）部分减少，没有患者 SRF 完全消失。八名患者接受了光动力治疗，一名患者接受了体外放射治疗。抢救治疗后，BCVA 的中位数从 6/60 变为 6/12（p = 0.63）。中位 CSFT 从 470 μm 显著降至 249 μm（p = 0.01）：结论：玻璃体内贝伐单抗不太可能成为治疗渗出性 CCH 的有效方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Retina-The Journal of Retinal and Vitreous Diseases 医学-眼科学

CiteScore

5.70

自引率

9.10%

发文量

554

审稿时长

3-6 weeks

期刊介绍： RETINA® focuses exclusively on the growing specialty of vitreoretinal disorders. The Journal provides current information on diagnostic and therapeutic techniques. Its highly specialized and informative, peer-reviewed articles are easily applicable to clinical practice. In addition to regular reports from clinical and basic science investigators, RETINA® publishes special features including periodic review articles on pertinent topics, special articles dealing with surgical and other therapeutic techniques, and abstract cards. Issues are abundantly illustrated in vivid full color. Published 12 times per year, RETINA® is truly a “must have” publication for anyone connected to this field.